ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $233,699 | $156,904 | $823,746 | $79,284 |
| % Growth | 48.9% | -81% | 939% | – |
| Cost of Goods Sold | $21,650 | $14,026 | $15,060 | $12,390 |
| Gross Profit | $212,049 | $142,878 | $808,688 | $66,894 |
| % Margin | 90.7% | 91.1% | 98.2% | 84.4% |
| R&D Expenses | $528,561 | $503,166 | $444,080 | $397,158 |
| G&A Expenses | $99,685 | $99,900 | $86,988 | $89,556 |
| SG&A Expenses | $237,472 | $206,498 | $176,626 | $201,804 |
| Sales & Mktg Exp. | $137,787 | $106,362 | $89,638 | $112,068 |
| Other Operating Expenses | $0 | $0 | -$2 | $0 |
| Operating Expenses | $766,033 | $709,664 | $620,704 | $598,962 |
| Operating Income | -$553,984 | -$566,786 | $187,984 | -$532,068 |
| % Margin | -237.1% | -361.2% | 22.8% | -671.1% |
| Other Income/Exp. Net | -$31,328 | $8,636 | -$25,089 | -$1,190 |
| Pre-Tax Income | -$585,312 | -$558,150 | $162,895 | -$533,258 |
| Tax Expense | $5,512 | $10,356 | $69 | -$9,896 |
| Net Income | -$590,768 | -$568,434 | $163,002 | -$523,286 |
| % Margin | -252.8% | -362.3% | 19.8% | -660% |
| EPS | -1.73 | -1.82 | 0.56 | -1.8 |
| % Growth | 4.9% | -425% | 131.1% | – |
| EPS Diluted | -1.73 | -1.82 | 0.55 | -1.8 |
| Weighted Avg Shares Out | 341,484 | 312,372 | 296,365 | 290,046 |
| Weighted Avg Shares Out Dil | 341,591 | 312,372 | 296,024 | 290,046 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,612 | $1,430 | $0 | $0 |
| Interest Expense | $0 | $0 | $28,044 | $20,280 |
| Depreciation & Amortization | $39,968 | $38,332 | $41,604 | $39,396 |
| EBITDA | -$514,016 | -$528,454 | $229,586 | -$492,672 |
| % Margin | -219.9% | -336.8% | 27.9% | -621.4% |